JP2005522438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005522438A5 JP2005522438A5 JP2003565975A JP2003565975A JP2005522438A5 JP 2005522438 A5 JP2005522438 A5 JP 2005522438A5 JP 2003565975 A JP2003565975 A JP 2003565975A JP 2003565975 A JP2003565975 A JP 2003565975A JP 2005522438 A5 JP2005522438 A5 JP 2005522438A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- phenyl
- methyl
- alkyl
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 C 1 -C 4 alkyl Chemical group 0.000 claims description 38
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 8
- DTUXNRWKSVIUOF-UHFFFAOYSA-N 1-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]-3-propylurea Chemical compound C1=CC(NC(=O)NCCC)=CC=C1N(C)C1=CC=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=N1 DTUXNRWKSVIUOF-UHFFFAOYSA-N 0.000 claims description 4
- 229940124530 sulfonamide Drugs 0.000 claims description 4
- LZWJEODSCLZMOY-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-5-yl)-3-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]urea Chemical compound C=1C=C(NC(=O)NC=2C=C3CCCC3=CC=2)C=CC=1N(C)C(N=1)=CC=NC=1NC1=CC=CC(CS(C)(=O)=O)=C1 LZWJEODSCLZMOY-UHFFFAOYSA-N 0.000 claims description 2
- NXPQZPWXVHIWGN-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-3-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]urea Chemical compound C=1C=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=O)NC1=C(Cl)C=CC=C1Cl NXPQZPWXVHIWGN-UHFFFAOYSA-N 0.000 claims description 2
- USCPNRWCYGQBGN-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-[4-[[2-(5-ethylsulfonyl-2-methoxyanilino)pyrimidin-4-yl]-methylamino]phenyl]urea Chemical compound CCS(=O)(=O)C1=CC=C(OC)C(NC=2N=C(C=CN=2)N(C)C=2C=CC(NC(=O)NC=3C=C(Cl)C=CC=3)=CC=2)=C1 USCPNRWCYGQBGN-UHFFFAOYSA-N 0.000 claims description 2
- RZFLHAKBZISSBN-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-[4-[[2-[3-(methanesulfonamidomethyl)anilino]pyrimidin-4-yl]-methylamino]phenyl]urea Chemical compound C=1C=NC(NC=2C=C(CNS(C)(=O)=O)C=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=O)NC1=CC=CC(Cl)=C1 RZFLHAKBZISSBN-UHFFFAOYSA-N 0.000 claims description 2
- ISIGZINVBPDMCU-UHFFFAOYSA-N 1-(3-fluorophenyl)-3-[4-[methyl-[2-[4-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]urea;hydrochloride Chemical compound Cl.C=1C=NC(NC=2C=CC(CS(C)(=O)=O)=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=O)NC1=CC=CC(F)=C1 ISIGZINVBPDMCU-UHFFFAOYSA-N 0.000 claims description 2
- GJRXTJDKSVWHHF-UHFFFAOYSA-N 1-(4-acetylphenyl)-3-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]urea Chemical compound C=1C=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C(C)=O)C=C1 GJRXTJDKSVWHHF-UHFFFAOYSA-N 0.000 claims description 2
- UIIXIQWTXSGBOP-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-[4-[methyl-[2-[4-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]urea Chemical compound C=1C=NC(NC=2C=CC(CS(C)(=O)=O)=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=O)NC1=CC=C(F)C=C1 UIIXIQWTXSGBOP-UHFFFAOYSA-N 0.000 claims description 2
- RREMTKSPGOIRHQ-UHFFFAOYSA-N 1-[2-(dimethylamino)ethyl]-3-[4-[methyl-[2-[3-(2-methylsulfonylethyl)anilino]pyrimidin-4-yl]amino]phenyl]urea Chemical compound C1=CC(NC(=O)NCCN(C)C)=CC=C1N(C)C1=CC=NC(NC=2C=C(CCS(C)(=O)=O)C=CC=2)=N1 RREMTKSPGOIRHQ-UHFFFAOYSA-N 0.000 claims description 2
- YBLPVRFSDNONDP-UHFFFAOYSA-N 1-[4-[[2-(5-ethylsulfonyl-2-methoxyanilino)pyrimidin-4-yl]-methylamino]phenyl]-3-(3-fluorophenyl)urea Chemical compound CCS(=O)(=O)C1=CC=C(OC)C(NC=2N=C(C=CN=2)N(C)C=2C=CC(NC(=O)NC=3C=C(F)C=CC=3)=CC=2)=C1 YBLPVRFSDNONDP-UHFFFAOYSA-N 0.000 claims description 2
- RYIZQWVKFLSVHM-UHFFFAOYSA-N 1-[4-[[2-(5-ethylsulfonyl-2-methoxyanilino)pyrimidin-4-yl]-methylamino]phenyl]-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea Chemical compound CCS(=O)(=O)C1=CC=C(OC)C(NC=2N=C(C=CN=2)N(C)C=2C=CC(NC(=O)NC=3C(=CC=C(C=3)C(F)(F)F)F)=CC=2)=C1 RYIZQWVKFLSVHM-UHFFFAOYSA-N 0.000 claims description 2
- DQXBQPHEQRETIN-UHFFFAOYSA-N 1-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]-3-(2-phenylethyl)urea Chemical compound C=1C=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=O)NCCC1=CC=CC=C1 DQXBQPHEQRETIN-UHFFFAOYSA-N 0.000 claims description 2
- ZMDSDIMLVJXMJA-UHFFFAOYSA-N 1-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]-3-[4-(trifluoromethoxy)phenyl]urea Chemical compound C=1C=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=O)NC1=CC=C(OC(F)(F)F)C=C1 ZMDSDIMLVJXMJA-UHFFFAOYSA-N 0.000 claims description 2
- RJINUSFBYKYLTQ-UHFFFAOYSA-N 1-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]-3-phenylthiourea Chemical compound C=1C=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=S)NC1=CC=CC=C1 RJINUSFBYKYLTQ-UHFFFAOYSA-N 0.000 claims description 2
- NJVJUCVNZRPMBF-UHFFFAOYSA-N 1-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]-3-phenylurea Chemical compound C=1C=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1 NJVJUCVNZRPMBF-UHFFFAOYSA-N 0.000 claims description 2
- GDFXLACGLHMCTE-UHFFFAOYSA-N 1-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]-3-propan-2-ylurea Chemical compound C1=CC(NC(=O)NC(C)C)=CC=C1N(C)C1=CC=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=N1 GDFXLACGLHMCTE-UHFFFAOYSA-N 0.000 claims description 2
- LVGQTXJDZKXBOC-UHFFFAOYSA-N 1-[4-[methyl-[2-[4-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]-3-(4-phenylmethoxyphenyl)urea Chemical compound C=1C=NC(NC=2C=CC(CS(C)(=O)=O)=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=O)NC(C=C1)=CC=C1OCC1=CC=CC=C1 LVGQTXJDZKXBOC-UHFFFAOYSA-N 0.000 claims description 2
- AHDFVTJYNGXCEO-UHFFFAOYSA-N 1-[4-[methyl-[2-[4-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]-3-[4-(4-methylpiperazine-1-carbonyl)phenyl]urea Chemical compound C=1C=NC(NC=2C=CC(CS(C)(=O)=O)=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=O)NC(C=C1)=CC=C1C(=O)N1CCN(C)CC1 AHDFVTJYNGXCEO-UHFFFAOYSA-N 0.000 claims description 2
- WUUXQSKAAWHECK-UHFFFAOYSA-N 1-[4-[methyl-[2-[4-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]-3-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]urea Chemical compound C=1C=NC(NC=2C=CC(CS(C)(=O)=O)=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=O)NC(C=C1)=CC=C1CN1CCN(C)CC1 WUUXQSKAAWHECK-UHFFFAOYSA-N 0.000 claims description 2
- CCGBGVNOJXOFAR-UHFFFAOYSA-N 1-butyl-3-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]urea Chemical compound C1=CC(NC(=O)NCCCC)=CC=C1N(C)C1=CC=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=N1 CCGBGVNOJXOFAR-UHFFFAOYSA-N 0.000 claims description 2
- HQILAAKXJCORFA-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]urea Chemical compound C=1C=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=O)NC1CCCCC1 HQILAAKXJCORFA-UHFFFAOYSA-N 0.000 claims description 2
- QCXCNKJISLRDOZ-UHFFFAOYSA-N 1-ethyl-3-[4-[methyl-[2-[4-[2-(methylsulfamoyl)ethyl]anilino]pyrimidin-4-yl]amino]phenyl]urea Chemical compound C1=CC(NC(=O)NCC)=CC=C1N(C)C1=CC=NC(NC=2C=CC(CCS(=O)(=O)NC)=CC=2)=N1 QCXCNKJISLRDOZ-UHFFFAOYSA-N 0.000 claims description 2
- VRVGEKJEMKGQCS-UHFFFAOYSA-N 1-tert-butyl-3-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]urea Chemical compound C=1C=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=NC=1N(C)C1=CC=C(NC(=O)NC(C)(C)C)C=C1 VRVGEKJEMKGQCS-UHFFFAOYSA-N 0.000 claims description 2
- WTTQMMJLQSHYGL-UHFFFAOYSA-N 2-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]-1-phenylguanidine Chemical compound C=1C=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=NC=1N(C)C(C=C1)=CC=C1N=C(N)NC1=CC=CC=C1 WTTQMMJLQSHYGL-UHFFFAOYSA-N 0.000 claims description 2
- XIDCNIZERXGXGB-UHFFFAOYSA-N CN(C1=CC=C(C=C1)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)F)C3=NC(=NC=C3)NC4=CC=CC=C4 Chemical compound CN(C1=CC=C(C=C1)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)F)C3=NC(=NC=C3)NC4=CC=CC=C4 XIDCNIZERXGXGB-UHFFFAOYSA-N 0.000 claims description 2
- MXUBDZBAYUHPDY-UHFFFAOYSA-N CN(C1=NC(=NC=C1)NC2=CC=CC=C2)C3=CC=CC(=C3)NC(=O)NC4=C(C=CC(=C4)C(F)(F)F)F Chemical compound CN(C1=NC(=NC=C1)NC2=CC=CC=C2)C3=CC=CC(=C3)NC(=O)NC4=C(C=CC(=C4)C(F)(F)F)F MXUBDZBAYUHPDY-UHFFFAOYSA-N 0.000 claims description 2
- VYWQTJWGWLKBQA-UHFFFAOYSA-N [amino(hydroxy)methylidene]azanium;chloride Chemical compound Cl.NC(N)=O VYWQTJWGWLKBQA-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- ROIHUUVUCIGOLZ-UHFFFAOYSA-N n-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]-1-phenylmethanesulfonamide Chemical compound C=1C=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=NC=1N(C)C(C=C1)=CC=C1NS(=O)(=O)CC1=CC=CC=C1 ROIHUUVUCIGOLZ-UHFFFAOYSA-N 0.000 claims description 2
- XGJGNIZVSIGIJT-UHFFFAOYSA-N n-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]-2-phenylacetamide Chemical compound C=1C=NC(NC=2C=C(CS(C)(=O)=O)C=CC=2)=NC=1N(C)C(C=C1)=CC=C1NC(=O)CC1=CC=CC=C1 XGJGNIZVSIGIJT-UHFFFAOYSA-N 0.000 claims description 2
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 56
- 239000001257 hydrogen Substances 0.000 claims 54
- 150000002431 hydrogen Chemical group 0.000 claims 51
- 125000000753 cycloalkyl group Chemical group 0.000 claims 33
- 125000000623 heterocyclic group Chemical group 0.000 claims 33
- 125000003545 alkoxy group Chemical group 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 21
- 125000004104 aryloxy group Chemical group 0.000 claims 20
- 125000004438 haloalkoxy group Chemical group 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical group 0.000 claims 13
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 13
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 11
- 125000001769 aryl amino group Chemical group 0.000 claims 10
- 125000001475 halogen functional group Chemical group 0.000 claims 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 7
- 239000000460 chlorine Substances 0.000 claims 7
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- SQQWBSBBCSFQGC-JLHYYAGUSA-N ubiquinone-2 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CCC=C(C)C)=C(C)C1=O SQQWBSBBCSFQGC-JLHYYAGUSA-N 0.000 claims 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 1
- RZBKPAOZLPAYEX-UHFFFAOYSA-N 1-methyl-1-[4-[methyl-[2-[3-(methylsulfonylmethyl)anilino]pyrimidin-4-yl]amino]phenyl]-3-phenylurea Chemical compound C=1C=C(N(C)C=2N=C(NC=3C=C(CS(C)(=O)=O)C=CC=3)N=CC=2)C=CC=1N(C)C(=O)NC1=CC=CC=C1 RZBKPAOZLPAYEX-UHFFFAOYSA-N 0.000 claims 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35504602P | 2002-02-08 | 2002-02-08 | |
| PCT/US2003/003816 WO2003066601A1 (en) | 2002-02-08 | 2003-02-07 | Pyrimidine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005522438A JP2005522438A (ja) | 2005-07-28 |
| JP2005522438A5 true JP2005522438A5 (enExample) | 2006-03-23 |
Family
ID=27734457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565975A Pending JP2005522438A (ja) | 2002-02-08 | 2003-02-07 | ピリミジン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7459455B2 (enExample) |
| EP (1) | EP1472233A1 (enExample) |
| JP (1) | JP2005522438A (enExample) |
| AU (1) | AU2003209077A1 (enExample) |
| CA (1) | CA2476281A1 (enExample) |
| MX (1) | MXPA04007637A (enExample) |
| WO (1) | WO2003066601A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL159120A0 (en) | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| DE502004004468D1 (de) * | 2003-07-22 | 2007-09-06 | Sungene Gmbh | Expressionskassetten zur bidirektionalen transgenen expression von nukleinsäuren in pflanzen |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| ATE542801T1 (de) * | 2003-08-15 | 2012-02-15 | Novartis Ag | Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine |
| AU2004272288B2 (en) * | 2003-09-18 | 2008-11-13 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| JP2007515957A (ja) * | 2003-12-12 | 2007-06-21 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | ガンの予示及び予後ならびにガン治療の監視のための方法 |
| US7799915B2 (en) * | 2004-10-13 | 2010-09-21 | Wyeth Llc | Anilino-pyrimidine analogs |
| ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| FR2888239B1 (fr) * | 2005-07-11 | 2008-05-09 | Sanofi Aventis Sa | Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| EA200800285A1 (ru) * | 2005-07-11 | 2008-08-29 | Санофи-Авентис | Новые производные 2,4-дианилинопиримидинов, их получение, лекарственные средства, фармацевтические композиции, содержащие указанные производные, и их применение, в частности, в качестве ингибиторов ikk |
| US7523289B2 (en) | 2005-09-30 | 2009-04-21 | Spectra Logic Corporation | Random access storage system capable of performing storage operations intended for alternative storage devices |
| WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| EA200802058A1 (ru) | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и их фармацевтические композиции |
| EP1873159A1 (en) * | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| EP1870416A1 (en) * | 2006-06-21 | 2007-12-26 | Bayer Schering Pharma Aktiengesellschaft | Sulphonamido-macrocycles as tie2 inhibitors |
| WO2008008234A1 (en) * | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| EP1878726A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same |
| EA019941B1 (ru) | 2006-12-08 | 2014-07-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| ES2539518T3 (es) * | 2007-04-24 | 2015-07-01 | Astrazeneca Ab | Inhibidores de proteínas quinasas |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| KR20100132550A (ko) | 2008-04-16 | 2010-12-17 | 포톨라 파마슈티컬스, 인코포레이티드 | ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드 |
| US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
| BRPI0910668A2 (pt) | 2008-04-22 | 2019-09-24 | Portola Pharmaceutiacals Inc | inibidores de proteína quinases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| AU2009262068C1 (en) * | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| JP2012507497A (ja) * | 2008-11-03 | 2012-03-29 | ジェネリクス・（ユーケー）・リミテッド | ボセンタンおよび関連物質のｈｐｌｃ分析方法、ならびに参照スタンダードまたはマーカーとしてのこれら物質の使用 |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| PH12013500246A1 (en) | 2010-08-10 | 2019-10-11 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| AU2011323484B2 (en) | 2010-11-01 | 2016-10-06 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as Syk modulators |
| EP2975027A1 (en) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
| WO2012061415A1 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
| BR112013010564B1 (pt) | 2010-11-01 | 2021-09-21 | Celgene Car Llc | Compostos heterocíclicos e composições compreendendo os mesmos |
| JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| JP2014532658A (ja) | 2011-10-28 | 2014-12-08 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ブルトン型チロシンキナーゼ疾患または障害を治療する方法 |
| EP2782579B1 (en) | 2011-11-23 | 2019-01-02 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
| UA114501C2 (uk) | 2012-02-28 | 2017-06-26 | Астеллас Фарма Інк. | Азотовмісна ароматична гетероциклічна сполука |
| ES2880109T3 (es) | 2012-03-15 | 2021-11-23 | Celgene Car Llc | Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico |
| JP6317320B2 (ja) | 2012-03-15 | 2018-04-25 | セルジーン シーエーアール エルエルシー | 上皮成長因子受容体キナーゼ阻害剤の塩 |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| WO2013173518A1 (en) * | 2012-05-16 | 2013-11-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| WO2014058921A2 (en) | 2012-10-08 | 2014-04-17 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| CN105188371A (zh) | 2013-02-08 | 2015-12-23 | 西建阿维拉米斯研究公司 | Erk抑制剂及其用途 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US20170114025A1 (en) * | 2014-05-15 | 2017-04-27 | Catalyst Therapeutics Pty Ltd | Methods for inhibiting necroptosis |
| WO2016025561A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Forms and compositions of an erk inhibitor |
| CA2976121A1 (en) * | 2015-02-10 | 2016-08-18 | Catalyst Therapeutics Pty Ltd | Inhibitors of necroptosis |
| EP4741018A3 (en) | 2020-06-19 | 2026-07-15 | Anaxis Pharma Pty Ltd | Sulphonamide compounds |
| JP2025501767A (ja) | 2021-12-22 | 2025-01-23 | アナシス・ファルマ・プロプライエタリー・リミテッド | アリールスルホンアミド化合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0813525B9 (en) | 1995-03-10 | 2004-02-04 | Berlex Laboratories, Inc. | Benzamidine derivatives their preparation and their use as anti-coagulants |
| US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| AU5438299A (en) * | 1998-08-29 | 2000-03-21 | Astrazeneca Ab | Pyrimidine compounds |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| AU5108000A (en) | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| KR20030024659A (ko) | 2000-02-17 | 2003-03-26 | 암겐 인코포레이티드 | 키나제 억제제 |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
-
2003
- 2003-02-07 US US10/503,874 patent/US7459455B2/en not_active Expired - Fee Related
- 2003-02-07 EP EP03707805A patent/EP1472233A1/en not_active Withdrawn
- 2003-02-07 JP JP2003565975A patent/JP2005522438A/ja active Pending
- 2003-02-07 MX MXPA04007637A patent/MXPA04007637A/es unknown
- 2003-02-07 AU AU2003209077A patent/AU2003209077A1/en not_active Abandoned
- 2003-02-07 CA CA002476281A patent/CA2476281A1/en not_active Abandoned
- 2003-02-07 WO PCT/US2003/003816 patent/WO2003066601A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2418652C (en) | Novel 3-substituted urea derivatives and medicinal use thereof | |
| JP2004517080A5 (enExample) | ||
| JP2006515858A5 (enExample) | ||
| JP2006506439A5 (enExample) | ||
| JP2011504485A5 (enExample) | ||
| JP2010522197A5 (enExample) | ||
| JP2008505874A5 (enExample) | ||
| JP2014502979A5 (enExample) | ||
| JP2005517672A5 (enExample) | ||
| AU7446600A (en) | Novel diarylamide derivatives and use thereof as medicines | |
| KR20120120956A (ko) | 알킬아민 유도체 | |
| RU2008146751A (ru) | Новые производные имидазола, их получение и использование в качестве лекартвенных средств | |
| US7868046B2 (en) | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | |
| CA2508618A1 (en) | Tetrahydro-naphthalene derivatives | |
| KR20140125737A (ko) | 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물 | |
| JP2008525500A5 (enExample) | ||
| JP2008542365A5 (enExample) | ||
| CA2508845A1 (en) | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | |
| RU2008129641A (ru) | Ингибиторы ccr9 активности | |
| JP2008519783A5 (enExample) | ||
| JP2022544803A5 (enExample) | ||
| JP2010526051A5 (enExample) | ||
| CN106543077A (zh) | N,n’‑双取代芳基硫脲衍生物及其合成方法和应用 | |
| TW201023854A (en) | Biphenylacetamide derivatives | |
| JP2007516211A5 (enExample) |